Nothing Special   »   [go: up one dir, main page]

Van Buren et al., 2009 - Google Patents

Elucidation of two major aggregation pathways in an IgG2 antibody

Van Buren et al., 2009

View HTML
Document ID
9233669765362300523
Author
Van Buren N
Rehder D
Gadgil H
Matsumura M
Jacob J
Publication year
Publication venue
Journal of pharmaceutical sciences

External Links

Snippet

Two major aggregation pathways observed in an IgG2 molecule are described. Different aggregate species generated by long-term incubation of the antibody at 37° C were collected by a semi-preparative size exclusion chromatography method. These purified …
Continue reading at www.jpharmsci.org (HTML) (other versions)

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/06Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins
    • A61K47/16Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Similar Documents

Publication Publication Date Title
Van Buren et al. Elucidation of two major aggregation pathways in an IgG2 antibody
Neergaard et al. Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass
JP5553963B2 (en) Methods for refolding recombinant antibodies
Iacob et al. Investigating monoclonal antibody aggregation using a combination of H/DX-MS and other biophysical measurements
Paul et al. Structure and function of purified monoclonal antibody dimers induced by different stress conditions
Cordoba et al. Non-enzymatic hinge region fragmentation of antibodies in solution
Lee et al. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product
Singh et al. Effect of polysorbate 80 quality on photostability of a monoclonal antibody
Yu et al. Investigation of N-terminal glutamate cyclization of recombinant monoclonal antibody in formulation development
Yan et al. Versatile, sensitive, and robust native LC–MS platform for intact mass analysis of protein drugs
Liu et al. Analysis of reduced monoclonal antibodies using size exclusion chromatography coupled with mass spectrometry
Franey et al. Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates
Svilenov et al. The ReFOLD assay for protein formulation studies and prediction of protein aggregation during long-term storage
Zheng et al. Investigating the degradation behaviors of a therapeutic monoclonal antibody associated with pH and buffer species
US20160231329A1 (en) A method for analysing a sample immunoglobulin molecules
Perico et al. Conformational implications of an inversed pH-dependent antibody aggregation
Arora et al. Correlating the effects of antimicrobial preservatives on conformational stability, aggregation propensity, and backbone flexibility of an IgG1 mAb
Chakraborty et al. Isolation of fibronectin type III like peptide from human placental extract used as wound healer
EP3160511B1 (en) Protein formulations
Li et al. Identification and characterization of monoclonal antibody fragments cleaved at the complementarity determining region using orthogonal analytical methods
Chen et al. The use of native cation‐exchange chromatography to study aggregation and phase separation of monoclonal antibodies
Jiang et al. Evaluation of heavy-chain C-terminal deletion on product quality and pharmacokinetics of monoclonal antibodies
Liu et al. Characterization of recombinant monoclonal antibody charge variants using WCX chromatography, icIEF and LC-MS/MS
Majumder et al. Impact of buffers on colloidal property and aggregation propensities of a bispecific antibody
Whitaker et al. Developability assessment of physicochemical properties and stability profiles of HIV-1 BG505 SOSIP. 664 and BG505 SOSIP. v4. 1-GT1. 1 gp140 envelope glycoprotein trimers as candidate vaccine antigens